TUMOUR BRCA TEST ALL YOUR NEWLY DIAGNOSED ADVANCED OVARIAN CANCER PATIENTS TO IDENTITY THOSE WHO MAY BENEFIT FROM LYNPARZA 1L1,2,13
- Capoluongo, E. et al. 2017. Guidance statement on BRCA1/2 tumour testing in ovarian cancer patients. Semin Oncol. 44:187-197
- Vergote, I. et al. 2016. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur. J. Cancer Oxf. Engl. 69:127–134
- Alsop, K. et al. 2012. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30, 2654–2663.
- Swisher, E. et al. 2008. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581–2586.
- Ledermann, J. et al. 2014. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861.
- Gourley, C. et al. 2010. Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28, 2505–2511.
- Tan, D. & Kaye, S. 2015. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Meet. 114–121. doi:10.14694/EdBook_AM.2015.35.114.
- Bolton, K. et al. 2012. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 307, 382–390.
- Petrucelli, N. et al. 2010. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet. Med. Off. J. Am. Coll. Med. Genet. 12, 245–259.
- Surbone, A. 2011. Social and ethical implications of BRCA testing. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 22 Suppl 1, i60-66.
- Finch, A. et al. 2006. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296, 185–192.
- Domchek, S. et al. 2010. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 304, 967–975.
- Ledermann, J. et al. 2016. Appendix 7: Ovarian cancer: eUpdate published online September 2016. Ann Oncol. 27(S5):145.
- Pal, T. et al. 2005. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 104(12):2807-2816.
- Pennington, KP. et al. 2014. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 20(3):764-775.
- Moschetta, M. et al. 2016. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 27, 1449–1455.
- Ngeow J et al. npj Genomic Medicine 2016;1:15006
- Vergote I et al. Facts Views Vis Obgyn 2016:8 (3):161-167
GB-17589 - Date of preparation: July 2019